دورية أكاديمية
أعرض في EDS

Insulin/IGF Axis and the Receptor for Advanced Glycation End Products: Role in Meta-inflammation and Potential in Cancer Therapy.

التفاصيل البيبلوغرافية
العنوان: Insulin/IGF Axis and the Receptor for Advanced Glycation End Products: Role in Meta-inflammation and Potential in Cancer Therapy.
المؤلفون: Vella V; Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, 95122 Catania, Italy., Lappano R; Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy., Bonavita E; IRCCS Humanitas Research Hospital, Laboratory of Cellular and Molecular Oncoimmunology, 20089 Rozzano, Italy., Maggiolini M; Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy., Clarke RB; Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Manchester M204GJ, UK., Belfiore A; Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, 95122 Catania, Italy., De Francesco EM; Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, 95122 Catania, Italy.
المصدر: Endocrine reviews [Endocr Rev] 2023 Jul 11; Vol. 44 (4), pp. 693-723.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 8006258 Publication Model: Print Cited Medium: Internet ISSN: 1945-7189 (Electronic) Linking ISSN: 0163769X NLM ISO Abbreviation: Endocr Rev Subsets: MEDLINE
أسماء مطبوعة: Publication: 2017- : New York : Oxford University Press
Original Publication: Chevy Chase, MD : Endocrine Society
مواضيع طبية MeSH: Neoplasms*/metabolism , Somatomedins*, Humans ; Glycation End Products, Advanced/metabolism ; Inflammation/metabolism ; Insulin ; Obesity/metabolism ; Receptor for Advanced Glycation End Products/metabolism ; Tumor Microenvironment
مستخلص: In metabolic conditions such as obesity and diabetes, which are associated with deregulated signaling of the insulin/insulin-like growth factor system (IIGFs), inflammation plays a dominant role. In cancer, IIGFs is implicated in disease progression, particularly during obesity and diabetes; however, further mediators may act in concert with IIGFs to trigger meta-inflammation. The receptor for advanced glycation end-products (RAGE) and its ligands bridge together metabolism and inflammation in obesity, diabetes, and cancer. Herein, we summarize the main mechanisms of meta-inflammation in malignancies associated with obesity and diabetes; we provide our readers with the most recent understanding and conceptual advances on the role of RAGE at the crossroad between impaired metabolism and inflammation, toward disease aggressiveness. We inform on the potential hubs of cross-communications driven by aberrant RAGE axis and dysfunctional IIGFs in the tumor microenvironment. Furthermore, we offer a rationalized view on the opportunity to terminate meta-inflammation via targeting RAGE pathway, and on the possibility to shut its molecular connections with IIGFs, toward a better control of diabetes- and obesity-associated cancers.
(© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.)
References: Carcinogenesis. 2008 Oct;29(10):2035-43. (PMID: 18689872)
Front Endocrinol (Lausanne). 2016 Sep 28;7:132. (PMID: 27733843)
Cancer Gene Ther. 2015 Jun;22(6):326-34. (PMID: 25908451)
Growth Factors. 2018 Aug;36(3-4):164-171. (PMID: 31084273)
J Natl Cancer Inst. 2014 Feb;106(2):djt373. (PMID: 24491301)
Leukemia. 2010 Nov;24(11):1940-50. (PMID: 20844560)
Biomed Pharmacother. 2017 Aug;92:468-478. (PMID: 28570981)
J Biol Chem. 1997 Jun 27;272(26):16498-506. (PMID: 9195959)
Biochim Biophys Acta Rev Cancer. 2022 May;1877(3):188705. (PMID: 35276232)
Lab Invest. 2014 Apr;94(4):422-9. (PMID: 24514068)
Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1199-208. (PMID: 24723555)
J Immunother Cancer. 2019 Oct 29;7(1):280. (PMID: 31665084)
J Cancer. 2021 Jan 1;12(2):518-529. (PMID: 33391448)
Cancer Res. 2014 Dec 15;74(24):7285-7297. (PMID: 25326491)
J Food Drug Anal. 2019 Oct;27(4):887-896. (PMID: 31590760)
J Exp Clin Cancer Res. 2017 Sep 2;36(1):115. (PMID: 28865485)
Int J Med Sci. 2014 Jun 08;11(8):841-9. (PMID: 24936148)
Molecules. 2021 Nov 08;26(21):. (PMID: 34771150)
Front Cell Dev Biol. 2020 Dec 08;8:608412. (PMID: 33364239)
J Clin Oncol. 2009 Dec 1;27(34):5800-7. (PMID: 19786654)
Cancer Lett. 2012 Sep 1;322(1):98-106. (PMID: 22361176)
J Biol Chem. 2001 Feb 2;276(5):3543-9. (PMID: 11063744)
J Cancer Res Clin Oncol. 2012 Jan;138(1):11-22. (PMID: 21947243)
J Immunol. 2015 Dec 1;195(11):5296-5308. (PMID: 26519530)
Nat Med. 2005 Feb;11(2):183-90. (PMID: 15685173)
J Clin Oncol. 2014 Jul 1;32(19):2059-66. (PMID: 24888810)
J Biol Chem. 2019 May 3;294(18):7516-7527. (PMID: 30885944)
Cancer Cell. 2016 Jul 11;30(1):147-160. (PMID: 27411589)
J Diabetes Metab Disord. 2020 Aug 26;19(2):1129-1138. (PMID: 33520830)
J Exp Clin Cancer Res. 2022 Feb 22;41(1):74. (PMID: 35193644)
Oncol Lett. 2018 Apr;15(4):4627-4634. (PMID: 29541234)
Oncogene. 2017 Mar;36(11):1559-1572. (PMID: 27669433)
FASEB J. 2008 May;22(5):1572-80. (PMID: 18089847)
Oncol Rep. 2013 Sep;30(3):1249-56. (PMID: 23836405)
Int J Cancer. 2012 Oct 15;131(8):1755-67. (PMID: 22287060)
Nucleic Acid Ther. 2020 Dec;30(6):402-413. (PMID: 32991252)
PLoS One. 2013 Sep 04;8(9):e72480. (PMID: 24023743)
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jul;1864(7):1017-1030. (PMID: 30953761)
Bioengineered. 2021 Dec;12(1):4995-5003. (PMID: 34369271)
Stem Cell Reports. 2022 Jun 14;17(6):1411-1427. (PMID: 35523180)
J Nutr. 2014 Feb;144(2):109-13. (PMID: 24285690)
Endocr Relat Cancer. 2019 Jan 1;26(1):197-214. (PMID: 30121624)
Cancer Biol Med. 2020 Feb 15;17(1):154-168. (PMID: 32296583)
PLoS One. 2017 Jan 23;12(1):e0170318. (PMID: 28114390)
Breast Cancer Res. 2017 Jun 19;19(1):70. (PMID: 28629450)
Mol Biol Cell. 2011 Sep;22(18):3344-54. (PMID: 21795396)
Mol Med. 2017 Nov;23:295-306. (PMID: 29387865)
Lancet. 2014 Aug 30;384(9945):755-65. (PMID: 25129328)
PLoS One. 2013 Sep 20;8(9):e76039. (PMID: 24073286)
J Pathol. 2018 Jun;245(2):197-208. (PMID: 29533466)
Pathol Oncol Res. 2017 Jan;23(1):73-77. (PMID: 27411924)
Ann Oncol. 2015 May;26(5):921-927. (PMID: 25609246)
Int J Obes (Lond). 2009 Jan;33(1):54-66. (PMID: 19050672)
Metabolism. 2019 Mar;92:136-146. (PMID: 30412695)
J Clin Endocrinol Metab. 1994 Sep;79(3):872-8. (PMID: 7521354)
Endocr Rev. 2017 Oct 1;38(5):379-431. (PMID: 28973479)
Hepatology. 2013 Jul;58(1):363-73. (PMID: 23504974)
J Clin Endocrinol Metab. 1998 May;83(5):1467-71. (PMID: 9589640)
Horm Metab Res. 2015 Aug;47(9):686-92. (PMID: 25611208)
Biochem Biophys Res Commun. 2020 Jan 1;521(1):77-83. (PMID: 31629469)
Neoplasma. 2021 Jan;68(1):71-78. (PMID: 33030958)
Clin Transl Med. 2021 Nov;11(11):e516. (PMID: 34841688)
J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18. (PMID: 17179482)
Nat Rev Cancer. 2008 Dec;8(12):915-28. (PMID: 19029956)
Trends Immunol. 2013 Jun;34(6):282-9. (PMID: 23434408)
Neoplasia. 2011 Feb;13(2):131-44. (PMID: 21403839)
Cancers (Basel). 2021 Aug 09;13(16):. (PMID: 34439167)
Biochem Biophys Res Commun. 2017 Nov 4;493(1):592-597. (PMID: 28867179)
Cancer Res. 2010 Jan 1;70(1):57-67. (PMID: 20048072)
Cell. 2010 Mar 19;140(6):805-20. (PMID: 20303872)
J Clin Invest. 2007 Jan;117(1):175-84. (PMID: 17200717)
Diabetologia. 2018 Oct;61(10):2140-2154. (PMID: 30027404)
Endocr Relat Cancer. 2011 Jul 04;18(4):R125-47. (PMID: 21606157)
Int J Mol Sci. 2019 Jul 01;20(13):. (PMID: 31266264)
Oncoimmunology. 2019 Jun 11;8(9):e1624129. (PMID: 31428521)
Am J Cancer Res. 2015 Apr 15;5(5):1741-50. (PMID: 26175942)
J Exp Clin Cancer Res. 2022 Feb 8;41(1):54. (PMID: 35135586)
Oncoimmunology. 2013 Jun 1;2(6):e24441. (PMID: 23894703)
J Cell Mol Med. 2020 Mar;24(5):3053-3063. (PMID: 32022398)
Cells. 2022 Aug 04;11(15):. (PMID: 35954247)
Immunobiology. 2015 May;220(5):539-44. (PMID: 25578401)
Annu Rev Med. 2018 Jan 29;69:349-364. (PMID: 29106804)
Biomed Res Int. 2015;2015:512027. (PMID: 26106610)
Nature. 2013 Apr 11;496(7444):238-42. (PMID: 23535595)
Mol Carcinog. 2015 Dec;54(12):1584-95. (PMID: 25307746)
Inflamm Res. 2019 Aug;68(8):639-642. (PMID: 31115587)
Cells. 2019 Sep 01;8(9):. (PMID: 31480557)
J Cell Physiol. 2020 Mar;235(3):2738-2752. (PMID: 31498430)
J Exp Med. 2008 Sep 29;205(10):2235-49. (PMID: 18809714)
Cell Tissue Res. 2006 Mar;323(3):475-88. (PMID: 16315007)
Diabet Med. 2013 Jun;30(6):702-9. (PMID: 23432638)
Cell Signal. 2022 Feb;90:110206. (PMID: 34856357)
Mol Cells. 2020 Sep 30;43(9):763-773. (PMID: 32759466)
Annu Rev Med. 2013;64:45-57. (PMID: 23121183)
Biol Res Nurs. 2021 Oct;23(4):698-707. (PMID: 34096348)
Oncol Lett. 2015 Jun;9(6):2864-2870. (PMID: 26137161)
Trends Endocrinol Metab. 2019 Dec;30(12):959-973. (PMID: 31597608)
Oncol Rep. 2019 Aug;42(2):817-825. (PMID: 31173265)
Cells. 2019 Oct 06;8(10):. (PMID: 31590432)
Oncoimmunology. 2019 Jun 11;8(9):e1605822. (PMID: 31428515)
Horm Cancer. 2018 Oct;9(5):295-325. (PMID: 29987748)
Cancer Cell. 2021 Jan 11;39(1):28-37. (PMID: 33125860)
Front Genet. 2021 Dec 21;12:703883. (PMID: 34992627)
Carcinogenesis. 2005 Feb;26(2):293-301. (PMID: 15539404)
Front Oncol. 2021 May 20;11:651693. (PMID: 34094941)
J Biol Chem. 1992 Jul 25;267(21):14987-97. (PMID: 1321822)
Acta Biomater. 2022 Mar 15;141:255-263. (PMID: 35081431)
Acta Diabetol. 2013 Jun;50(3):443-9. (PMID: 23447004)
Nat Immunol. 2017 Jul 19;18(8):843-850. (PMID: 28722707)
Clin Cancer Res. 2013 Jul 15;19(14):3764-75. (PMID: 23719262)
Endocrinology. 2018 Apr 1;159(4):1658-1677. (PMID: 29370351)
Cancer Metastasis Rev. 2011 Dec;30(3-4):311-24. (PMID: 22005953)
Nat Immunol. 2017 Mar;18(3):283-292. (PMID: 28092375)
J Immunol. 2015 Jun 15;194(12):6082-9. (PMID: 25964487)
Int J Cancer. 2003 May 10;104(6):722-7. (PMID: 12640679)
Clin Cancer Res. 2007 Oct 1;13(19):5834-40. (PMID: 17908976)
Nature. 2000 May 18;405(6784):354-60. (PMID: 10830965)
Mol Cell Endocrinol. 2002 Nov 29;197(1-2):153-65. (PMID: 12431808)
Cell Physiol Biochem. 2001;11(4):173-86. (PMID: 11509825)
J Exp Med. 2022 May 2;219(5):. (PMID: 35404390)
J Cell Sci. 2006 Feb 1;119(Pt 3):470-81. (PMID: 16418226)
Sci Transl Med. 2021 Nov 24;13(621):eabf7084. (PMID: 34818060)
Adv Exp Med Biol. 2020;1226:73-86. (PMID: 32030677)
J Lipid Res. 2005 Nov;46(11):2347-55. (PMID: 16150820)
Endocr Rev. 2009 Oct;30(6):586-623. (PMID: 19752219)
Nat Immunol. 2011 May;12(5):408-15. (PMID: 21478880)
Biochem Biophys Res Commun. 2016 Sep 2;477(4):963-969. (PMID: 27387233)
Int J Mol Sci. 2021 Oct 02;22(19):. (PMID: 34639040)
Cancer Res. 2015 Mar 15;75(6):974-85. (PMID: 25572331)
Cell Stem Cell. 2014 Jun 5;14(6):810-23. (PMID: 24905167)
Exp Ther Med. 2018 Jan;15(1):242-246. (PMID: 29375686)
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3777-82. (PMID: 9108054)
Cancer Res. 2008 Oct 15;68(20):8322-32. (PMID: 18922904)
Tumour Biol. 2016 Apr;37(4):4399-408. (PMID: 26499944)
Cell Immunol. 2021 Jul;365:104379. (PMID: 34038758)
Cell Physiol Biochem. 2017;42(6):2507-2522. (PMID: 28848092)
Mediators Inflamm. 2021 May 5;2021:9958051. (PMID: 34035661)
Clin Pharmacol Ther. 2014 Oct;96(4):458-63. (PMID: 24960521)
Int J Oncol. 2008 Sep;33(3):493-501. (PMID: 18695878)
J Clin Invest. 2003 Dec;112(12):1821-30. (PMID: 14679177)
Cancer Res. 2012 Feb 1;72(3):604-15. (PMID: 22158945)
Oncogene. 2014 Jan 30;33(5):567-77. (PMID: 23318458)
Tumour Biol. 2016 Mar;37(3):3321-9. (PMID: 26440051)
Life Sci. 2020 May 15;249:117503. (PMID: 32142767)
Cell Metab. 2012 Aug 8;16(2):265-73. (PMID: 22883234)
Endocr Relat Cancer. 2009 Dec;16(4):1103-23. (PMID: 19620249)
PLoS One. 2019 May 17;14(5):e0216358. (PMID: 31100066)
Biomolecules. 2021 Apr 01;11(4):. (PMID: 33915939)
Int J Obes Relat Metab Disord. 1997 May;21(5):355-9. (PMID: 9152736)
Cell Death Discov. 2021 Sep 7;7(1):236. (PMID: 34493714)
Bioorg Med Chem Lett. 2021 Dec 15;54:128444. (PMID: 34763082)
J Immunol. 2013 Feb 1;190(3):1372-9. (PMID: 23269246)
Diabetes. 2001 Dec;50(12):2792-808. (PMID: 11723063)
Mol Cancer. 2017 Jan 30;16(1):6. (PMID: 28137302)
Annu Rev Pathol. 2016 May 23;11:421-49. (PMID: 27193454)
Cancers (Basel). 2021 Feb 04;13(4):. (PMID: 33557316)
Autophagy. 2012 Jun;8(6):989-91. (PMID: 22722139)
Front Immunol. 2019 Sep 18;10:2243. (PMID: 31620141)
NPJ Precis Oncol. 2017;1:. (PMID: 29152592)
Oncol Rep. 2010 Dec;24(6):1541-50. (PMID: 21042750)
Cell Metab. 2006 Jul;4(1):13-24. (PMID: 16814729)
Cell Commun Signal. 2020 Oct 27;18(1):170. (PMID: 33109194)
Angiogenesis. 2022 May;25(2):181-203. (PMID: 34617194)
J Oncol. 2019 Sep 4;2019:7387601. (PMID: 31565056)
Oncoimmunology. 2012 Oct 1;1(7):1165-1166. (PMID: 23170266)
Oncotarget. 2016 Aug 16;7(33):52710-52728. (PMID: 27384677)
Cell. 2009 Sep 4;138(5):961-75. (PMID: 19737522)
Nat Med. 2017 Nov;23(11):1319-1330. (PMID: 28967919)
Nat Med. 2019 Dec;25(12):1822-1832. (PMID: 31806905)
Antioxidants (Basel). 2019 Mar 04;8(3):. (PMID: 30836666)
Mol Cell Endocrinol. 1995 Jun;111(2):159-65. (PMID: 7556877)
Cardiovasc Diabetol. 2015 Jan 13;14:2. (PMID: 25582643)
Cancer Res. 2019 Jun 1;79(11):2909-2922. (PMID: 30737234)
Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998)
Nat Commun. 2019 Nov 1;10(1):5016. (PMID: 31676788)
Oncogene. 2017 Dec 7;36(49):6749-6761. (PMID: 28825725)
Diabetes Res Clin Pract. 2007 May;76(2):236-44. (PMID: 17097186)
Med Oncol. 2014 Jan;31(1):805. (PMID: 24338270)
Nat Rev Endocrinol. 2014 Nov;10(11):644-5. (PMID: 25265978)
Aging (Albany NY). 2020 Jan 6;12(1):593-610. (PMID: 31905169)
J Immunol. 2010 Jul 1;185(1):605-14. (PMID: 20498354)
J Biol Chem. 1992 Jul 25;267(21):14998-5004. (PMID: 1378843)
Cell Death Dis. 2014 Oct 23;5:e1480. (PMID: 25341034)
Cancer Res. 2014 Dec 1;74(23):6806-19. (PMID: 25252914)
J Immunother Cancer. 2021 Mar;9(3):. (PMID: 33712445)
Oncogene. 2018 Apr;37(15):2022-2036. (PMID: 29367764)
Physiol Rev. 2015 Jul;95(3):727-48. (PMID: 26084689)
Annu Rev Physiol. 2010;72:219-46. (PMID: 20148674)
Adipocyte. 2020 Dec;9(1):563-566. (PMID: 32892690)
Glia. 2011 Mar;59(3):486-98. (PMID: 21264954)
Diabetologia. 2016 Mar;59(3):512-21. (PMID: 26634571)
Diabetes. 2008 Dec;57(12):3239-46. (PMID: 18829989)
JAMA. 2022 May 24;327(20):1963-1973. (PMID: 35608580)
Trends Endocrinol Metab. 2006 Oct;17(8):328-36. (PMID: 16956771)
Int J Mol Sci. 2018 Nov 28;19(12):. (PMID: 30487448)
Nat Med. 2011 Feb;17(2):179-88. (PMID: 21217695)
Mol Med Rep. 2018 Jun;17(6):8536-8541. (PMID: 29693146)
Cancer Lett. 2015 Dec 28;369(2):396-404. (PMID: 26404752)
BMC Cancer. 2022 May 24;22(1):578. (PMID: 35610613)
Science. 2001 Aug 31;293(5535):1673-7. (PMID: 11533494)
Sci Rep. 2016 Jul 18;6:29914. (PMID: 27426915)
Biochem Biophys Res Commun. 2020 Oct 20;531(3):422-430. (PMID: 32800556)
J Immunol. 2015 Jun 1;194(11):5539-48. (PMID: 25911757)
Int J Cancer. 2015 Jul 15;137(2):345-58. (PMID: 25492101)
J Clin Invest. 1992 Aug;90(2):439-46. (PMID: 1322940)
Neoplasma. 2010;57(1):55-61. (PMID: 19895173)
Microvasc Res. 2014 Sep;95:1-6. (PMID: 24984291)
Oncol Rep. 2015 Apr;33(4):1630-8. (PMID: 25652880)
Eur J Pharmacol. 2010 Mar 10;629(1-3):153-8. (PMID: 20004657)
Science. 2014 Sep 26;345(6204):1250684. (PMID: 25258083)
Trends Immunol. 2002 Nov;23(11):549-55. (PMID: 12401408)
PLoS One. 2014 Oct 16;9(10):e110542. (PMID: 25330185)
Anticancer Res. 2019 Dec;39(12):6743-6750. (PMID: 31810939)
Int J Oncol. 2018 Sep;53(3):973-986. (PMID: 30015880)
Biochim Biophys Acta. 2015 Mar;1852(3):429-41. (PMID: 25514746)
Anticancer Drugs. 2010 Feb;21(2):181-5. (PMID: 19966562)
Nat Med. 2014 Jun;20(6):676-81. (PMID: 24859530)
J Biol Chem. 2012 Jun 1;287(23):18985-94. (PMID: 22493510)
Cell Commun Signal. 2009 May 08;7:12. (PMID: 19426472)
Nat Immunol. 2014 Sep;15(9):846-55. (PMID: 25086775)
Sci Rep. 2016 Jan 05;6:18822. (PMID: 26729520)
Int J Oncol. 2018 Oct;53(4):1481-1492. (PMID: 30066846)
Mol Carcinog. 2019 Apr;58(4):500-510. (PMID: 30456802)
J Exp Clin Cancer Res. 2018 Aug 29;37(1):205. (PMID: 30157958)
Diabetes. 2012 Jan;61(1):104-13. (PMID: 22148072)
J Biol Chem. 2004 Jun 11;279(24):25157-63. (PMID: 15069075)
Cells. 2021 Nov 12;10(11):. (PMID: 34831367)
Cancers (Basel). 2021 Sep 17;13(18):. (PMID: 34572888)
Nutrients. 2022 Mar 05;14(5):. (PMID: 35268073)
Cell Res. 2013 Jul;23(7):898-914. (PMID: 23752925)
Nature. 2008 Jul 24;454(7203):436-44. (PMID: 18650914)
Mol Cell Endocrinol. 2014 Sep;395(1-2):69-78. (PMID: 25111846)
Int J Obes (Lond). 2014 Dec;38(12):1545-54. (PMID: 24577317)
Oncogene. 2022 Jan;41(4):600-611. (PMID: 34785779)
Cancer Res. 2006 Jul 1;66(13):6699-707. (PMID: 16818644)
BMC Cancer. 2015 Feb 12;15:44. (PMID: 25884510)
Cell Signal. 2021 Jan;77:109819. (PMID: 33147518)
Clin Cancer Res. 2015 Dec 15;21(24):5453-9. (PMID: 26289067)
Mol Med Rep. 2018 Apr;17(4):5202-5212. (PMID: 29393459)
Diabetes Care. 2014;37(1):88-95. (PMID: 23959566)
Cancer Microenviron. 2018 Dec;11(2-3):97-105. (PMID: 30091031)
Oncol Rep. 2020 Dec;44(6):2547-2558. (PMID: 33125145)
Clin Cancer Res. 2012 Aug 15;18(16):4356-64. (PMID: 22718861)
Oncogene. 2010 Apr 8;29(14):2083-92. (PMID: 20101226)
Diabetes. 2013 Feb;62(2):478-89. (PMID: 23011593)
Anticancer Drugs. 2019 Mar;30(3):225-232. (PMID: 30334817)
Front Cardiovasc Med. 2020 Feb 25;7:22. (PMID: 32158768)
J Clin Oncol. 2011 Oct 20;29(30):4022-8. (PMID: 21931019)
Circ Res. 2016 May 27;118(11):1723-35. (PMID: 27230638)
FEBS Lett. 2003 Aug 28;550(1-3):107-13. (PMID: 12935895)
Redox Biol. 2016 Aug;8:91-7. (PMID: 26771767)
PLoS One. 2011;6(8):e23132. (PMID: 21829704)
J Immunol. 2000 Jun 15;164(12):6166-73. (PMID: 10843666)
J Cancer. 2016 Nov 26;7(15):2346-2359. (PMID: 27994674)
Stem Cells. 2017 Feb;35(2):325-336. (PMID: 27501952)
Am J Physiol Endocrinol Metab. 2008 Mar;294(3):E568-75. (PMID: 18171910)
Nature. 2017 Feb 8;542(7640):177-185. (PMID: 28179656)
Endocr Rev. 2009 Apr;30(2):152-77. (PMID: 19240267)
J Exp Med. 2008 Feb 18;205(2):275-85. (PMID: 18208974)
JAKSTAT. 2013 Apr 1;2(2):e23878. (PMID: 24058813)
Br J Cancer. 2016 Jun 28;115(1):76-9. (PMID: 27195423)
Cancer Res. 2011 Mar 1;71(5):1912-23. (PMID: 21169409)
Oncogene. 2002 Nov 28;21(54):8240-50. (PMID: 12447687)
Redox Biol. 2017 Oct;13:370-385. (PMID: 28667906)
Mediators Inflamm. 2013;2013:713859. (PMID: 24453427)
Ageing Res Rev. 2015 Nov;24(Pt A):66-76. (PMID: 26197086)
Horm Metab Res. 2013 May;45(5):387-90. (PMID: 23225247)
J Hepatol. 2014 Feb;60(2):319-24. (PMID: 24045151)
Dis Colon Rectum. 2007 Aug;50(8):1230-40. (PMID: 17587138)
Breast Cancer Res. 2017 Dec 6;19(1):129. (PMID: 29212519)
Front Oncol. 2013 Sep 12;3:232. (PMID: 24062985)
Oncotarget. 2017 Jun 12;8(34):56126-56142. (PMID: 28915578)
Immunity. 2019 Jul 16;51(1):27-41. (PMID: 31315034)
IUBMB Life. 2015 May;67(5):361-73. (PMID: 25983116)
Cancer Invest. 2007 Dec;25(8):720-5. (PMID: 18058469)
J Exp Clin Cancer Res. 2022 Jun 3;41(1):193. (PMID: 35655319)
Diabetologia. 2016 Oct;59(10):2181-92. (PMID: 27468708)
J Biol Chem. 2007 Nov 30;282(48):35279-92. (PMID: 17916553)
J Allergy Clin Immunol. 2020 Oct;146(4):694-705. (PMID: 32771559)
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E625-E635. (PMID: 32101031)
Biomolecules. 2021 Jun 22;11(7):. (PMID: 34206590)
Pathobiology. 2009;76(4):155-62. (PMID: 19571604)
Mol Cell Probes. 2020 Aug;52:101583. (PMID: 32360740)
Nat Med. 2022 Apr;28(4):752-765. (PMID: 35411077)
Thyroid. 2015 May;25(5):514-27. (PMID: 25744544)
Adipocyte. 2013 Jul 1;2(3):176-83. (PMID: 23991365)
Biogerontology. 2019 Jun;20(3):279-301. (PMID: 30968282)
Cancer Res. 2016 Feb 15;76(4):974-83. (PMID: 26837769)
Int J Mol Sci. 2021 Mar 05;22(5):. (PMID: 33807620)
Clin Cancer Res. 2018 Aug 1;24(15):3704-3716. (PMID: 29703820)
PLoS One. 2013 Aug 19;8(8):e72138. (PMID: 23977231)
Cell Death Dis. 2021 Sep 22;12(10):858. (PMID: 34552063)
J Immunol. 2019 Mar 15;202(6):1786-1797. (PMID: 30718296)
Cancer Lett. 2015 Feb 28;357(2):527-34. (PMID: 25511739)
Cancer Genet Cytogenet. 2010 Jul 15;200(2):140-8. (PMID: 20620597)
Mediators Inflamm. 2013;2013:591056. (PMID: 23365488)
Horm Res. 1999;51(2):53-67. (PMID: 10352394)
PLoS One. 2013;8(3):e58100. (PMID: 23472139)
J Pathol. 2017 Nov;243(3):376-389. (PMID: 28802057)
Oncogene. 2022 Jul;41(28):3625-3639. (PMID: 35688943)
J Clin Med. 2014 Dec 22;3(4):1561-74. (PMID: 26237614)
J Clin Invest. 2017 Jan 3;127(1):43-54. (PMID: 28045398)
Cell Rep. 2012 May 31;1(5):444-52. (PMID: 22708078)
BMC Cancer. 2013 Nov 16;13:549. (PMID: 24237932)
Int J Immunopathol Pharmacol. 2012 Oct-Dec;25(4):955-65. (PMID: 23298486)
Nature. 2021 Jul;595(7868):578-584. (PMID: 34135508)
Cell Death Dis. 2020 Apr 23;11(4):265. (PMID: 32327633)
Diabetes Care. 2011 Jul;34(7):1610-6. (PMID: 21709297)
Nat Rev Drug Discov. 2022 Nov;21(11):799-820. (PMID: 35974096)
Diabetes. 2014 Jun;63(6):1948-65. (PMID: 24520121)
Oncoimmunology. 2020 Feb 14;9(1):1725355. (PMID: 32117590)
Stem Cell Reports. 2019 Apr 9;12(4):816-830. (PMID: 30905741)
Nat Commun. 2022 Mar 18;13(1):1481. (PMID: 35304461)
PLoS One. 2011 Apr 29;6(4):e19375. (PMID: 21559403)
Nat Rev Immunol. 2022 Mar;22(3):173-187. (PMID: 34230649)
Biochim Biophys Acta Mol Basis Dis. 2017 Nov;1863(11):2808-2820. (PMID: 28712835)
Exp Ther Med. 2021 May;21(5):470. (PMID: 33767765)
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1339-1350. (PMID: 33629304)
Int J Mol Sci. 2013 Apr 11;14(4):7959-78. (PMID: 23579957)
Lancet Oncol. 2015 Jan;16(1):36-46. (PMID: 25467404)
Cell Signal. 2020 Aug;72:109631. (PMID: 32275943)
Mol Cancer Ther. 2010 Oct;9(10):2652-64. (PMID: 20924128)
Cells. 2019 Jun 06;8(6):. (PMID: 31174324)
Antioxidants (Basel). 2019 Nov 15;8(11):. (PMID: 31731716)
Curr Mol Med. 2010 Jun;10(4):369-73. (PMID: 20455855)
Cytokine. 2015 Jun;73(2):265-9. (PMID: 25802195)
J Control Release. 2018 Jun 10;279:40-52. (PMID: 29660374)
Nat Rev Immunol. 2016 Jul;16(7):407-20. (PMID: 27291964)
Oncol Lett. 2017 Jul;14(1):525-532. (PMID: 28693201)
Clin Biochem. 2010 Jul;43(10-11):882-6. (PMID: 20398646)
Am J Physiol Lung Cell Mol Physiol. 2013 Oct 1;305(7):L491-500. (PMID: 23997170)
Invest New Drugs. 2012 Dec;30(6):2433-42. (PMID: 22415797)
J Biol Chem. 2008 Dec 19;283(51):35507-16. (PMID: 18952609)
Cell Death Dis. 2018 Sep 26;9(10):1004. (PMID: 30258050)
Cell Death Dis. 2020 May 21;11(5):383. (PMID: 32439949)
Am J Pathol. 1993 Dec;143(6):1699-712. (PMID: 8256857)
J Clin Invest. 2003 Dec;112(12):1796-808. (PMID: 14679176)
Endocr Rev. 2020 Feb 1;41(1):. (PMID: 31722374)
Oncogene. 2017 Mar 2;36(9):1276-1286. (PMID: 27546618)
Biochim Biophys Acta Gen Subj. 2017 May;1861(5 Pt A):1065-1074. (PMID: 28237576)
Oncogene. 2018 Jun;37(23):3131-3150. (PMID: 29540831)
Biochim Biophys Acta. 2000 Dec 20;1498(2-3):99-111. (PMID: 11108954)
Clin Cancer Res. 2016 Jan 15;22(2):301-9. (PMID: 26324738)
Mol Genet Genomic Med. 2019 Feb;7(2):e00528. (PMID: 30556321)
Diabetologia. 2005 Jun;48(6):1038-50. (PMID: 15864529)
Transl Oncol. 2022 Jan 25;17:101350. (PMID: 35091340)
Cancer Sci. 2013 Jun;104(6):740-9. (PMID: 23421467)
Oncol Res. 2019 Jun 21;27(6):713-727. (PMID: 30850029)
Cancer Cell Int. 2021 Dec 21;21(1):700. (PMID: 34933679)
PLoS One. 2014 May 07;9(5):e94151. (PMID: 24804677)
PLoS One. 2015 Dec 21;10(12):e0145404. (PMID: 26689911)
J Clin Invest. 2011 Jun;121(6):2111-7. (PMID: 21633179)
Cell Rep. 2019 Jul 16;28(3):773-791.e7. (PMID: 31315054)
فهرسة مساهمة: Keywords: RAGE; cancer; diabetes; insulin/IGF system; meta-inflammation; obesity
المشرفين على المادة: 0 (Glycation End Products, Advanced)
0 (Insulin)
0 (Receptor for Advanced Glycation End Products)
0 (Somatomedins)
0 (AGER protein, human)
تواريخ الأحداث: Date Created: 20230304 Date Completed: 20230718 Latest Revision: 20230718
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10335176
DOI: 10.1210/endrev/bnad005
PMID: 36869790
قاعدة البيانات: MEDLINE
الوصف
تدمد:1945-7189
DOI:10.1210/endrev/bnad005